Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management

A. Evoli, R. Liguori, A. Romani, R. Mantegazza, A. Di Muzio, B. Giometto, E. Pegoraro, C. Rodolico, M. C. Vigliani

Research output: Contribution to journalArticle

Abstract

Lambert-Eaton myasthenic syndrome (LEMS) is a pre-synaptic disorder of the neuromuscular and autonomic transmission mediated by antibodies to voltage-gated calcium channels at the motor nerve terminal. LEMS is a quite rare and probably under-diagnosed disease: the onset may be slow and clinical signs are typically fluctuating, thus adding to the delay in diagnosis. LEMS weakness typically involves lower and upper limbs and the proximal muscles are predominantly affected. A significant proportion of patients also have dysfunction of the autonomic nervous system that may include dry mouth, constipation, blurred vision, impaired sweating, and orthostatic hypotension. LEMS recognition is based on clinical, electrophysiological and immunological criteria. Nearly 50-60 % of patients with LEMS have an underlying tumour that, in almost all cases, is a small-cell lung cancer; the onset of neurological symptoms generally precedes tumour detection. A careful screening for the early detection of the possible associated cancer is a crucial step for optimal disease management. The Italian Working Group on Myasthenic Syndromes developed diagnostic and therapeutic algorithms that could serve in routine clinical practice as tools for a patient-tailored approach.

Original languageEnglish
Pages (from-to)515-520
Number of pages6
JournalNeurological Sciences
Volume35
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Lambert-Eaton Myasthenic Syndrome
Neuromuscular Junction Diseases
Neoplasms
Orthostatic Hypotension
Sweating
Autonomic Nervous System
Muscle Weakness
Small Cell Lung Carcinoma
Constipation
Calcium Channels
Disease Management
Mouth
Lower Extremity
Muscles
Antibodies

Keywords

  • 3,4-Diaminopyridine
  • Lambert-Eaton myasthenic syndrome
  • Small-cell lung cancer
  • Voltage-gated calcium channel antibodies

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. / Evoli, A.; Liguori, R.; Romani, A.; Mantegazza, R.; Di Muzio, A.; Giometto, B.; Pegoraro, E.; Rodolico, C.; Vigliani, M. C.

In: Neurological Sciences, Vol. 35, No. 4, 2014, p. 515-520.

Research output: Contribution to journalArticle

Evoli, A, Liguori, R, Romani, A, Mantegazza, R, Di Muzio, A, Giometto, B, Pegoraro, E, Rodolico, C & Vigliani, MC 2014, 'Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management', Neurological Sciences, vol. 35, no. 4, pp. 515-520. https://doi.org/10.1007/s10072-014-1637-4
Evoli, A. ; Liguori, R. ; Romani, A. ; Mantegazza, R. ; Di Muzio, A. ; Giometto, B. ; Pegoraro, E. ; Rodolico, C. ; Vigliani, M. C. / Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. In: Neurological Sciences. 2014 ; Vol. 35, No. 4. pp. 515-520.
@article{69461230243d4e6cbcb72a890230f16a,
title = "Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management",
abstract = "Lambert-Eaton myasthenic syndrome (LEMS) is a pre-synaptic disorder of the neuromuscular and autonomic transmission mediated by antibodies to voltage-gated calcium channels at the motor nerve terminal. LEMS is a quite rare and probably under-diagnosed disease: the onset may be slow and clinical signs are typically fluctuating, thus adding to the delay in diagnosis. LEMS weakness typically involves lower and upper limbs and the proximal muscles are predominantly affected. A significant proportion of patients also have dysfunction of the autonomic nervous system that may include dry mouth, constipation, blurred vision, impaired sweating, and orthostatic hypotension. LEMS recognition is based on clinical, electrophysiological and immunological criteria. Nearly 50-60 {\%} of patients with LEMS have an underlying tumour that, in almost all cases, is a small-cell lung cancer; the onset of neurological symptoms generally precedes tumour detection. A careful screening for the early detection of the possible associated cancer is a crucial step for optimal disease management. The Italian Working Group on Myasthenic Syndromes developed diagnostic and therapeutic algorithms that could serve in routine clinical practice as tools for a patient-tailored approach.",
keywords = "3,4-Diaminopyridine, Lambert-Eaton myasthenic syndrome, Small-cell lung cancer, Voltage-gated calcium channel antibodies",
author = "A. Evoli and R. Liguori and A. Romani and R. Mantegazza and {Di Muzio}, A. and B. Giometto and E. Pegoraro and C. Rodolico and Vigliani, {M. C.}",
year = "2014",
doi = "10.1007/s10072-014-1637-4",
language = "English",
volume = "35",
pages = "515--520",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "4",

}

TY - JOUR

T1 - Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management

AU - Evoli, A.

AU - Liguori, R.

AU - Romani, A.

AU - Mantegazza, R.

AU - Di Muzio, A.

AU - Giometto, B.

AU - Pegoraro, E.

AU - Rodolico, C.

AU - Vigliani, M. C.

PY - 2014

Y1 - 2014

N2 - Lambert-Eaton myasthenic syndrome (LEMS) is a pre-synaptic disorder of the neuromuscular and autonomic transmission mediated by antibodies to voltage-gated calcium channels at the motor nerve terminal. LEMS is a quite rare and probably under-diagnosed disease: the onset may be slow and clinical signs are typically fluctuating, thus adding to the delay in diagnosis. LEMS weakness typically involves lower and upper limbs and the proximal muscles are predominantly affected. A significant proportion of patients also have dysfunction of the autonomic nervous system that may include dry mouth, constipation, blurred vision, impaired sweating, and orthostatic hypotension. LEMS recognition is based on clinical, electrophysiological and immunological criteria. Nearly 50-60 % of patients with LEMS have an underlying tumour that, in almost all cases, is a small-cell lung cancer; the onset of neurological symptoms generally precedes tumour detection. A careful screening for the early detection of the possible associated cancer is a crucial step for optimal disease management. The Italian Working Group on Myasthenic Syndromes developed diagnostic and therapeutic algorithms that could serve in routine clinical practice as tools for a patient-tailored approach.

AB - Lambert-Eaton myasthenic syndrome (LEMS) is a pre-synaptic disorder of the neuromuscular and autonomic transmission mediated by antibodies to voltage-gated calcium channels at the motor nerve terminal. LEMS is a quite rare and probably under-diagnosed disease: the onset may be slow and clinical signs are typically fluctuating, thus adding to the delay in diagnosis. LEMS weakness typically involves lower and upper limbs and the proximal muscles are predominantly affected. A significant proportion of patients also have dysfunction of the autonomic nervous system that may include dry mouth, constipation, blurred vision, impaired sweating, and orthostatic hypotension. LEMS recognition is based on clinical, electrophysiological and immunological criteria. Nearly 50-60 % of patients with LEMS have an underlying tumour that, in almost all cases, is a small-cell lung cancer; the onset of neurological symptoms generally precedes tumour detection. A careful screening for the early detection of the possible associated cancer is a crucial step for optimal disease management. The Italian Working Group on Myasthenic Syndromes developed diagnostic and therapeutic algorithms that could serve in routine clinical practice as tools for a patient-tailored approach.

KW - 3,4-Diaminopyridine

KW - Lambert-Eaton myasthenic syndrome

KW - Small-cell lung cancer

KW - Voltage-gated calcium channel antibodies

UR - http://www.scopus.com/inward/record.url?scp=84897429789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897429789&partnerID=8YFLogxK

U2 - 10.1007/s10072-014-1637-4

DO - 10.1007/s10072-014-1637-4

M3 - Article

C2 - 24481713

AN - SCOPUS:84897429789

VL - 35

SP - 515

EP - 520

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 4

ER -